Q8BM55
Gene name |
Tmem214 |
Protein name |
Transmembrane protein 214 |
Names |
|
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:68796 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q8BM55
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q8BM55-F1 | Predicted | AlphaFoldDB |
33 variants for Q8BM55
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs264204466 | 33 | S>G | No | EVA | |
| rs3395405959 | 152 | K>R | No | EVA | |
| rs3388754390 | 176 | R>L | No | EVA | |
| rs231500776 | 187 | T>I | No | EVA | |
| rs3388742678 | 200 | C>S | No | EVA | |
| rs3388746895 | 209 | D>N | No | EVA | |
| rs3388751633 | 210 | K>N | No | EVA | |
| rs3388751856 | 212 | P>S | No | EVA | |
| rs3388723806 | 224 | Q>E | No | EVA | |
| rs3388746869 | 227 | L>M | No | EVA | |
| rs3388740347 | 233 | I>T | No | EVA | |
| rs3388752103 | 306 | P>H | No | EVA | |
| rs246952710 | 376 | S>N | No | EVA | |
| rs3388754349 | 399 | S>N | No | EVA | |
| rs3388742735 | 410 | H>L | No | EVA | |
| rs236307898 | 427 | H>Q | No | EVA | |
| rs3388737087 | 432 | A>V | No | EVA | |
| rs259840709 | 445 | V>F | No | EVA | |
| rs3388747893 | 454 | G>V | No | EVA | |
| rs3388751550 | 456 | G>R | No | EVA | |
| rs3388737089 | 469 | K>R | No | EVA | |
| rs3388750989 | 538 | Q>R | No | EVA | |
| rs3388745091 | 541 | N>D | No | EVA | |
| rs3388745156 | 572 | I>M | No | EVA | |
| rs241988947 | 574 | S>G | No | EVA | |
| rs3388752070 | 574 | S>T | No | EVA | |
| rs3388749310 | 583 | Y>C | No | EVA | |
| rs227510825 | 592 | A>T | No | EVA | |
| rs3388750967 | 600 | L>P | No | EVA | |
| rs230272868 | 621 | S>N | No | EVA | |
| rs3388751900 | 630 | L>Q | No | EVA | |
| rs3388737103 | 639 | E>D | No | EVA | |
| rs32458115 | 658 | L>F | No | EVA |
No associated diseases with Q8BM55
No regional properties for Q8BM55
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| No domain, repeats, and functional sites for Q8BM55 | |||
6 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasmic microtubule | Any microtubule in the cytoplasm of a cell. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| endoplasmic reticulum | The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached). |
| endoplasmic reticulum membrane | The lipid bilayer surrounding the endoplasmic reticulum. |
| Golgi apparatus | A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. |
| integral component of membrane | The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
No GO annotations of molecular function
| Name | Definition |
|---|---|
| No GO annotations for molecular function |
1 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
1 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q6NUQ4 | TMEM214 | Transmembrane protein 214 | Homo sapiens (Human) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAARSAGSGG | WEVVKRGRRP | GASSGGRGGG | GGSDRRALGE | ANGVLKYDLS | SPIQTTSTLY |
| 70 | 80 | 90 | 100 | 110 | 120 |
| ERGFEKIMKR | QNKEQVPPPA | AESKKPINKK | QPKKVTAVPS | QNQKQGPFRR | LEDALKALDV |
| 130 | 140 | 150 | 160 | 170 | 180 |
| AALQKELDKS | QSVFTGNPSV | WLKDLASYLN | YKLQTPRMEP | TLSQYPHDYP | YSLVSRELRG |
| 190 | 200 | 210 | 220 | 230 | 240 |
| IIRGLLTKAA | GSVELFFDHC | LFTMLQELDK | TPGESLHGYR | ICIQAVLQDK | PKIVTSNLDK |
| 250 | 260 | 270 | 280 | 290 | 300 |
| FLELLRSHQS | RPAKCLTIMW | ALGQAGFTNL | TEGLKVWLGI | MLPVLGIKAL | SPFAIAYLDR |
| 310 | 320 | 330 | 340 | 350 | 360 |
| LLLMHPNLTK | GFGMIGPKDF | FPLLDFAYMP | NNSLSPSLQE | QLCQLFPRLK | VLAFGAKPES |
| 370 | 380 | 390 | 400 | 410 | 420 |
| SLHTYFPSFL | SRATPSCPAA | MKKELLASLT | QCLTVDPLST | SVWRQLYPKH | LSQSSLLLEH |
| 430 | 440 | 450 | 460 | 470 | 480 |
| LLKSWEHIPK | KARKSLQETI | QSLKVTNQEL | LKKGSGGSEH | VLTCDTACKG | LLQRARGPRP |
| 490 | 500 | 510 | 520 | 530 | 540 |
| PWARLFLLLL | VFAVGFLCHD | LRSNSSLQAS | LTGRLLRSSG | LLPVGQQVCA | RLSSYSLQSY |
| 550 | 560 | 570 | 580 | 590 | 600 |
| NWLQETLPAC | GSHLLAVVQP | SLQLAWTHIY | AIFSFLSAHC | ASYLACFSDS | LAGFFQRVQL |
| 610 | 620 | 630 | 640 | 650 | 660 |
| PEALQQLFHA | LKELLLLFCH | SVLLPTWHLL | LAALAQVQEH | CHEACRGDVT | WDCIKTQLSR |
| 670 | 680 | ||||
| AAQWTWLCLQ | DVTVAFLDWA | LTMISQQ |